Pemigatinib

Pemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells. It is grouped under the following drug class(es): Kinase inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Pemazyre, 3-(2, 6-difluoro-3, 5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1, 3, 4, 7-tetrahydro-2H-pyrrolo[3′, 2′:5, 6]pyrido[4 and 3-d]pyrimidin-2-one. Its PubChem CID is 86705695.

CAS No 1513857-77-6
Molecular Formula C24H27F2N5O4
Molecular Weight 487.5 g/mol
Synonyms 11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one

Frequently Asked Questions